Century Therapeutics Future Growth
Future criteria checks 1/6
Century Therapeutics's earnings are forecast to decline at 18% per annum while its annual revenue is expected to grow at 18.6% per year. EPS is expected to grow by 23.2% per annum.
Key information
-18.0%
Earnings growth rate
23.2%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | 18.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Nov 2024 |
Recent future growth updates
Recent updates
Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101
Jun 20Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 4 | -158 | N/A | N/A | 6 |
| 12/31/2024 | 3 | -127 | N/A | N/A | 6 |
| 9/30/2024 | 3 | -130 | -113 | -112 | N/A |
| 6/30/2024 | 2 | -131 | -103 | -97 | N/A |
| 3/31/2024 | 1 | -133 | -99 | -89 | N/A |
| 12/31/2023 | 2 | -137 | -102 | -88 | N/A |
| 9/30/2023 | 2 | -129 | -104 | -85 | N/A |
| 6/30/2023 | 5 | -127 | -121 | -96 | N/A |
| 3/31/2023 | 6 | -125 | -133 | -102 | N/A |
| 12/31/2022 | 5 | -131 | -17 | 14 | N/A |
| 9/30/2022 | 5 | -127 | -28 | 13 | N/A |
| 6/30/2022 | 2 | -123 | -34 | 13 | N/A |
| 3/31/2022 | 1 | -115 | -27 | 20 | N/A |
| 12/31/2021 | N/A | -96 | -134 | -89 | N/A |
| 9/30/2021 | N/A | -83 | -108 | -78 | N/A |
| 6/30/2021 | N/A | -70 | -82 | -63 | N/A |
| 3/31/2021 | N/A | -62 | -66 | -57 | N/A |
| 12/31/2020 | N/A | -54 | -51 | -41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IPSC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IPSC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IPSC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IPSC's revenue (18.6% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: IPSC's revenue (18.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IPSC's Return on Equity is forecast to be high in 3 years time